

Acquisition of Vivasure Medical Limited

January 9, 2026

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for the operation of Haemonetics, (ii) the anticipated benefits to Haemonetics arising from the completion of the acquisition, (iii) the impact of the acquisition on Haemonetics' business strategy and future business and operational performance, and (iv) the assumptions underlying or relating to any such statement. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the failure to realize the anticipated benefits of the acquisition or the acquisition having an unanticipated impact; Haemonetics' ability to predict accurately the demand for products and products under development by it or Vivasure Medical Limited and to develop strategies to successfully address relevant markets; actual and anticipated achievement of the future sales growth and other milestones on which contingent consideration is based; the impact of competitive products and pricing; regulatory uncertainties, including in the receipt or timing of regulatory approvals; technical innovations that could render products marketed or under development by Haemonetics or Vivasure Medical Limited obsolete and risks related to the use and protection of intellectual property. These and other factors are identified and described in more detail in Haemonetics' filings with the U.S. Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.

Acquisition of Vivasure



Founded in **2009**

Headquartered in **Galway, Ireland**

The company develops advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery.


ACQUISITION SUMMARY

- €100M upfront cash payment (~€52M net after adjusting for certain prior investments and loans), plus up to €85M of contingent consideration tied to sales growth and milestone achievement.

FINANCIAL CONSIDERATIONS

- Expands the Interventional Technologies (IVT) portfolio in the fast-growing large-bore closure market with clinically differentiated technology, securing category leadership in vascular closure.
- Leverages existing commercial scale and global reach to strengthen relevance with physicians, IDNs, and GPOs.
- Advances long-term IVT growth strategy through portfolio and market expansion opportunities and operational synergies.


Unlocks a Fast-Growing TAM With Innovative, Clinically Differentiated Technology




PerQseal[®] Elite

Single-use, fully bioabsorbable, patch-based device for vascular closure of 14–22F sheaths (up to 26F in OD).


Designed for purpose



Simple and secure device deployment



Patch based fully absorbable implant



Ease of use: Fully absorbable sutureless design, with no need to preclose.





Low complication rate: Zero major complications and less than 2% minor complications through 30-day follow up⁵.

Effective closure: Immediate median time to hemostasis⁶.

1) Procedure information was derived from Clarivate. 2) Large Bore market is defined as >14F. 3) TAM is calculated as procedures multiplied by the expected average selling price of the PerQseal Elite devices. 4) High Single Digits 5) Results from the prospective, single-arm, multi-center ELITE study; N=106 arterial per-protocol subjects, access site device-related vascular complications per VARC-3 definition. 6) Results from the prospective, single-arm, multi-center ELITE study; N=109 arterial, per-protocol closures. 7) PerQseal Elite is available for sale in the EU; Not available for sale in the US, pending PMA approval for arterial indication.

Secures Category Leadership in Advanced Closure

from 5F up to 22F in ID (up to 26F in OD)

			
VASCADE®	VASCADE MVP®	VASCADE MVP® XL	PerQseal® Elite¹
5F 7F	6F 12F	10F 12F 14F	14F 22F
Sheath Femoral Arterial and Venous Closure System	Sheath Femoral Venous Closure System (up to 15F OD)	Sheath Femoral Venous Closure System (up to 17F OD ²)	Sheath Femoral Arterial and Venous Closure System (up to 26F OD)

1) PerQseal Elite is available for sale in the EU; Not available for sale in the US, pending PMA approval for arterial indication. 2) VASCADE MVP® XL is pending FDA approval for label expansion up to 14F ID (up to 17F OD).